Dataset Information


Ethyl acetate fraction of Amomum xanthioides improves bile duct ligation-induced liver fibrosis of rat model via modulation of pro-fibrogenic cytokines.

ABSTRACT: We investigated anti-hepatofibrotic effects of ethyl acetate fraction of Ammomum xanthoides (EFAX) using bile duct ligation (BDL)-induced hepatic fibrosis in a rat model. Male SD rats (6 weeks old) underwent BDL followed by 15 days of orall administration of EFAX (12.5, 25 or 50 mg/kg) or ursodeoxycholic acid (25 mg/kg). BDL caused animal death, ascites formation, alterations in serum biochemistries, and severe hepatic injury with excessive collagen deposition, whereas EFAX treatment significantly attenuated these effects. BDL markedly increased the pro-fibrogenic cytokines (TGF-?, PDGF-?, and CTGF) and the extracellular matrix indicators ?-SMA, TIMP-1 and collagen type 1 in hepatic proteins and gene expression levels, which were notably normalized by EFAX treatment. EFAX also markedly normalized pro-fibrogenic signaling molecules including Smad2/3, Smad7, Akt, p44/42, and p38. We further explored EFAX mechanisms of actions using LX-2 cells (human derived hepatic stellate cell line). Pre-treatment with EFAX drastically attenuated the activation of ?-SMA and Smad2/3, which are downstream molecules of TGF-?. These findings suggest that EFAX may be a potent anti-hepatofibrotic agent, and its corresponding mechanisms primarily involve the modulation of pro-fibrogenic cytokines.


PROVIDER: S-EPMC4585957 | BioStudies | 2015-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4253459 | BioStudies
2012-01-01 | S-EPMC3544017 | BioStudies
2013-01-01 | S-EPMC3859579 | BioStudies
2005-01-01 | S-EPMC1196331 | BioStudies
2009-01-01 | S-EPMC2741443 | BioStudies
1000-01-01 | S-EPMC5406384 | BioStudies
1000-01-01 | S-EPMC4494934 | BioStudies
2016-01-01 | S-EPMC4821480 | BioStudies
| S-EPMC3069505 | BioStudies
2008-01-01 | S-EPMC4222180 | BioStudies